@article{cc95d6211674411e9d9119addfe5d364,
title = "On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2",
keywords = "abiraterone, cabazitaxel, docetaxel, enzalutamide, antiandrogen, androgen deprivation therapy, cancer mortality, cancer recurrence, cancer registry, castration resistant prostate cancer, coronavirus disease 2019, human, infection risk, Letter, priority journal, prostate cancer, Severe acute respiratory syndrome coronavirus 2, Betacoronavirus, Coronavirus infection, male, pandemic, prostate tumor, severe acute respiratory syndrome, virus pneumonia, Androgen Antagonists, Coronavirus Infections, Humans, Male, Pandemics, Pneumonia, Viral, Prostatic Neoplasms, Severe Acute Respiratory Syndrome",
author = "O. Caffo and V. Zagonel and C. Baldessari and A. Berruti and R. Bortolus and S. Buti and G.L. Ceresoli and M. Donini and P. Ermacora and G. Fornarini and L. Fratino and C. Masini and F. Massari and A. Mosca and C. Mucciarini and G. Procopio and M. Tucci and E. Verri and P. Zucali and C. Buttigliero",
note = "Cited By :3 Export Date: 26 February 2021 CODEN: ANONE",
year = "2020",
doi = "10.1016/j.annonc.2020.06.005",
language = "English",
volume = "31",
pages = "1415--1416",
journal = "Ann. Oncol.",
issn = "0923-7534",
publisher = "Elsevier Ltd",
number = "10",
}